Answers are grounded in this paper and cite their sources.
This editorial highlights the importance of understanding the epidemiology and management of rare respiratory diseases like pulmonary arterial hypertension.
A rare disease affects less than one in 2,000 individuals within the general population 1, 2. By nature, rare diseases concern a low number of patients, families and healthcare providers. This often has negative consequences for the patients, who may suffer from less than optimal care 1, 2. Rare respiratory diseases are no exception and it is time to improve awareness, as well as understanding of the epidemiology, pathophysiology and management, of these conditions 2. In the current issue of the European Respiratory Journal , Peacock et al. 3 provide novel original data on the epidemiology of pulmonary arterial hypertension (PAH) in Scotland (UK). PAH describes a group of noninfectious, nonmalignant respiratory diseases causing breathlessness, loss of exercise capacity and death due to elevated pulmonary artery pressure and subsequent right heart failure 4. A definite diagnosis of PAH requires strict right heart catheter criteria. Indeed, PAH is defined by an elevation of the mean pulmonary artery pressure >25 mmHg at rest and/or 30 mmHg during exercise without elevation of the pulmonary capillary wedge pressure (<15 mmHg), and elimination of frequent causes such as hypoxia, respiratory diseases and thrombo-embolic disease 4. Half of all PAH cases referred to pulmonary vascular centres have no identifiable risk factor, corresponding to idiopathic (sporadic) and familial PAH.
No takes yet. Share an insight, caveat, or question.
Marc Humbert (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: